Posted by Michael Wonder on 17 Feb 2021
Verrica Pharmaceuticals announces FDA filing acceptance of resubmitted new drug application for VP-102 for the treatment of molluscum contagiosum
17 February 2021 - PDUFA goal date assigned is 23 June 2021.
Verrica Pharmaceuticals today announced that its resubmitted new drug application for VP-102 (cantharidin 0.7% topical solution), a proprietary topical therapy for the treatment of molluscum contagiosum, has been accepted for filing by the U.S. FDA.
